Technology ID
TAB-4861
TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights
E-Numbers
E-040-2020-0
Lead Inventor
Farci, Patrizia (NIAID)
Co-Inventors
Sekhar, Vandana (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Lead IC
NIAID
ICs
NIAID
This technology involves studying the role of the Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) gene in Hepatitis C Virus (HCV) infection and hepatocellular carcinoma. Researchers perform transcriptomics analysis on liver specimens from HCV-infected patients, identify TACSTD2 as a key gene, and create a stable cell line that overexpresses TACSTD2 to investigate its impact on HCV infection and replication. This technology aims to provide insights into the molecular mechanisms of HCV infection and its association with liver cancer.
Commercial Applications
This technology has versatile potential applications. It can enhance our understanding of HCV infection mechanisms, leading to new treatments for HCV-related liver diseases. Additionally, the TACSTD2-overexpressing cell line offers opportunities for broader molecular studies. Its transcriptomics approach may also inspire similar investigations in other viral infections, advancing our knowledge of infectious diseases and aiding in treatment development.
Competitive Advantages
This technology's competitive advantages stem from its focused approach on the TACSTD2 gene, leveraging cutting-edge transcriptomics analysis to identify differentially expressed genes in HCV-infected patients, and establishing a stable cell line overexpressing TACSTD2 for precise experiments. With a direct link to HCV-associated hepatocellular carcinoma, it offers clinical relevance and the potential for therapeutic insights. Its applicability extends beyond HCV research, making it a versatile tool for various biomedical investigations, ultimately contributing to advancements in understanding HCV infection and its implications in liver diseases.
Licensing Contact: